AtaiBeckley Inc. Reports $1.7M Revenue in Q2 2026, Net Loss Widens to $32.5M

AtaiBeckley Inc. reported its financial results for the second quarter of 2026, revealing a total revenue of $1.7 million, a significant increase from $719,000 in the same period last year. This growth was primarily driven by license revenue of $437,000, compared to none in the prior year, and research and development services revenue of $1.3 million, up from $719,000. Despite this revenue growth, the company incurred a net loss of $32.5 million for the quarter, widening from a loss of $27.7 million in Q2 2025. The increase in losses was attributed to a substantial rise in operating expenses, which totaled $45.8 million, up from $26 million a year earlier.

The company's operating expenses were significantly impacted by research and development costs, which surged to $28.1 million from $11.1 million, reflecting increased investment in clinical trials and personnel following the strategic combination with Beckley Psytech. General and administrative expenses also rose to $17.8 million, compared to $14.9 million in the previous year, largely due to higher personnel costs and legal fees. The total operating loss for the quarter was $44.1 million, compared to $25.3 million in the same quarter of 2025.

AtaiBeckley has made notable strategic advancements, including the ongoing development of its product pipeline, which features several investigational therapies for mental health conditions. The company is currently conducting Phase 3 trials for its lead product, BPL-003, and has initiated a Phase 2b study for VLS-01. The company also reported a cash position of $168.8 million as of June 30, 2026, an increase from $85.3 million at the end of 2025, bolstered by cash inflows from the sale of investments and securities.

Looking ahead, AtaiBeckley is navigating a pivotal moment as it has entered into a merger agreement with Eli Lilly and Company, which is expected to close in the third quarter of 2026, pending shareholder and regulatory approvals. Under the terms of the agreement, shareholders will receive $6.75 in cash per share, along with contingent value rights that could yield additional payments based on the achievement of specific clinical and regulatory milestones. The company anticipates that its existing cash reserves will be sufficient to fund operations for at least the next 12 months, although it acknowledges the potential need for additional financing if the merger does not proceed as planned.